| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized (frommouse) |
| Target | Complement component 5 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
 N Y (what is this?) (verify) | |
Pexelizumab is adrug designed to reduce side effects ofcoronary artery bypass grafting[1] andangioplasty,[2][3] among other types ofcardiac surgery. It is asingle chain variable fragment of amonoclonal antibody targeted againstcomponent 5 of thecomplement system.[4]
Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.[5]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
